These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 36377880)

  • 1. A New Benzothiazolthiazolidine Derivative, 11726172, Is Active
    Salina EG; Postiglione U; Chiarelli LR; Recchia D; Záhorszká M; Lepioshkin A; Monakhova N; Pál A; Porta A; Zanoni G; Korduláková J; Kazakova E; Sassera D; Pasca MR; Makarov V; Degiacomi G
    mSphere; 2022 Dec; 7(6):e0036922. PubMed ID: 36377880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fighting tuberculosis by drugs targeting nonreplicating
    Iacobino A; Piccaro G; Giannoni F; Mustazzolu A; Fattorini L
    Int J Mycobacteriol; 2017; 6(3):213-221. PubMed ID: 28776518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
    Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
    Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques.
    Lin PL; Dartois V; Johnston PJ; Janssen C; Via L; Goodwin MB; Klein E; Barry CE; Flynn JL
    Proc Natl Acad Sci U S A; 2012 Aug; 109(35):14188-93. PubMed ID: 22826237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New 1-hydroxy-2-thiopyridine derivatives active against both replicating and dormant Mycobacterium tuberculosis.
    Salina EG; Ryabova O; Vocat A; Nikonenko B; Cole ST; Makarov V
    J Infect Chemother; 2017 Nov; 23(11):794-797. PubMed ID: 28527650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
    Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G
    Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Tool to Identify Bactericidal Compounds against Vulnerable Targets in Drug-Tolerant M. tuberculosis found in Caseum.
    Sarathy JP; Xie M; Jones RM; Chang A; Osiecki P; Weiner D; Tsao WS; Dougher M; Blanc L; Fotouhi N; Via LE; Barry CE; De Vlaminck I; Sherman DR; Dartois VA
    mBio; 2023 Apr; 14(2):e0059823. PubMed ID: 37017524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum.
    Sarathy JP; Via LE; Weiner D; Blanc L; Boshoff H; Eugenin EA; Barry CE; Dartois VA
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Host-pathogen interactions in latent Mycobacterium tuberculosis infection: identification of new targets for tuberculosis intervention.
    Lin MY; Ottenhoff TH
    Endocr Metab Immune Disord Drug Targets; 2008 Mar; 8(1):15-29. PubMed ID: 18393920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deletion of
    Khan MZ; Nandicoori VK
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33468473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dynamic reinfection hypothesis of latent tuberculosis infection.
    Cardona PJ
    Infection; 2009 Apr; 37(2):80-6. PubMed ID: 19308318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The significance of persisters in tuberculosis drug discovery: Exploring the potential of targeting the glyoxylate shunt pathway.
    Negi A; Sharma R
    Eur J Med Chem; 2024 Feb; 265():116058. PubMed ID: 38128237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Chemical Scaffolds Targeting Drug-Resistant and Latent
    Perveen S; Negi A; Saini S; Gangwar A; Sharma R
    ACS Infect Dis; 2024 Feb; 10(2):513-526. PubMed ID: 38238154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting dormant bacilli to fight tuberculosis.
    Fattorini L; Piccaro G; Mustazzolu A; Giannoni F
    Mediterr J Hematol Infect Dis; 2013 Nov; 5(1):e2013072. PubMed ID: 24363887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delamanid Kills Dormant Mycobacteria
    Chen X; Hashizume H; Tomishige T; Nakamura I; Matsuba M; Fujiwara M; Kitamoto R; Hanaki E; Ohba Y; Matsumoto M
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373190
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Liu R; Dang JN; Lee R; Lee JJ; Kesavamoorthy N; Ameri H; Rao N; Eoh H
    Microbiol Spectr; 2024 Aug; 12(8):e0078824. PubMed ID: 38916325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Not to wake a sleeping giant: new insights into host-pathogen interactions identify new targets for vaccination against latent Mycobacterium tuberculosis infection.
    Lin MY; Ottenhoff TH
    Biol Chem; 2008 May; 389(5):497-511. PubMed ID: 18953716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.